Dr. Elizabeth McDonald

We've spent the last year, along with the Eastern Cooperative Oncology Group, the American College of Radiology, and the TMIST Clinical Trial Group, that's the mammographic screening trial that's currently ongoing, to design and develop a clinical trial to test whether these drugs are causal in reducing the incidence of breast cancer.

So even though GLP-1 agonists have been shown to impact

multiple different cancer types, lung, colon, breast, liver, and even leukemia.

The ideal format for the clinical trial is to look at breast cancer incidence because breast is such a common cancer impacting one in eight women.

So you can have enough events to power the clinical trial with the least amount of people.